HC Wainwright Issues Optimistic Outlook for Clene Earnings

Clene Inc. (NASDAQ:CLNN) – Research analysts at HC Wainwright boosted their Q2 2025 earnings per share estimates for Clene in a report issued on Wednesday, May 7th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.39) for the quarter, up from their prior estimate of ($1.15). HC Wainwright has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. HC Wainwright also issued estimates for Clene’s Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($1.83) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at $2.33 EPS and FY2028 earnings at $7.18 EPS.

Clene (NASDAQ:CLNN) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.60. Clene had a negative return on equity of 1,106.30% and a negative net margin of 8,556.77%. The business had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.07 million.

Other equities analysts have also recently issued research reports about the company. Benchmark reduced their price target on Clene from $84.00 to $33.00 and set a “buy” rating for the company in a report on Thursday, May 8th. D. Boral Capital restated a “buy” rating and set a $23.00 price objective on shares of Clene in a research report on Thursday, May 8th. Finally, Jones Trading started coverage on shares of Clene in a research report on Wednesday, April 23rd. They set a “buy” rating and a $30.00 price objective for the company. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $40.00.

Clene Stock Performance

Clene stock opened at $2.64 on Monday. Clene has a 52 week low of $2.55 and a 52 week high of $9.20. The stock has a market capitalization of $23.72 million, a P/E ratio of -0.50 and a beta of 0.46. The stock has a 50-day simple moving average of $3.29 and a 200 day simple moving average of $4.28.

Institutional Investors Weigh In On Clene

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC raised its position in shares of Clene by 52.9% in the fourth quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock valued at $346,000 after buying an additional 22,539 shares in the last quarter. Fullcircle Wealth LLC acquired a new stake in shares of Clene in the fourth quarter valued at approximately $69,000. Renaissance Technologies LLC acquired a new stake in shares of Clene in the fourth quarter valued at approximately $96,000. Parsons Capital Management Inc. RI acquired a new stake in shares of Clene in the fourth quarter valued at approximately $194,000. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of Clene in the fourth quarter valued at approximately $69,000. 23.28% of the stock is currently owned by institutional investors and hedge funds.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.